ホーム › 卵巣がん › オハイオ

オハイオにおける卵巣がんの臨床試験

オハイオ内の拠点で、卵巣がんに関する70件の研究が参加者を募集しています。

オハイオ内の都市

公式研究テキスト（英語）

The Vanguard Study: Testing a New Way to Screen for Cancer

Louis Stokes Cleveland VA Medical Center, Cleveland

被験者募集中健康なボランティア歓迎

45歳〜75歳 · 全性別 · 2026/10/05更新 · NCT06995898

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

Ohio State University Comprehensive Cancer Center, Columbus

被験者募集中第2/3相

18歳以上 · 全性別 · 2026/10/05更新 · NCT07001748

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

OhioHealth O'Bleness Hospital, Athens
UH Seidman Cancer Center at UH Avon Health Center, Avon
UHHS-Chagrin Highlands Medical Center, Beachwood
他39件

被験者募集中第2相

全年齢 · 全性別 · 2026/10/05更新 · NCT05564377

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Research Site, Columbus

被験者募集中第1/2相

18歳〜130歳 · 全性別 · 2026/10/05更新 · NCT05797168

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

University Hospitals Cleveland Medical Center, Cleveland

被験者募集中第1相

18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Cleveland Clinic Taussig Cancer Center, Cleveland

被験者募集中第1/2相

12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Cleveland Clinic - Oncology Department, Cleveland

被験者募集中第2相

18歳以上 · 全性別 · 2026/10/02更新 · NCT06760819

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

University of Cincinnati Medical Center. /ID# 278925, Cincinnati
University Hospitals Cleveland Medical Center /ID# 279601, Cleveland

被験者募集中第2相

18歳以上 · 女性 · 2026/10/01更新 · NCT07024784

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer

Research Site, Cleveland

被験者募集中第3相

18歳以上 · 女性 · 2026/10/01更新 · NCT07851025

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

Site 06, Maumee

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/30更新 · NCT07814248

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

Cleveland Clinic, Cleveland

被験者募集中観察研究

18歳以上 · 女性 · 2026/09/29更新 · NCT05051722

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Metrohealth Medical Center - Cleveland /ID# 276664, Cleveland
Cleveland Clinic - Cleveland /ID# 276133, Cleveland
Cleveland Clinic - Cleveland /ID# 278273, Cleveland
他3件

被験者募集中第2相

18歳以上 · 女性 · 2026/09/29更新 · NCT06890338

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Site 0147 - Trihealth Cancer Institute - Harold and Eugen, Cincinnati
Site 0243 - Mark H Zangmeister Cancer Center, Columbus
Site 0214-Ohio State University Comprehensive Cancer Center, Hilliard

被験者募集中第2相

18歳以上 · 女性 · 2026/09/29更新 · NCT05128825

Study of AVZO-021 in Patients With Advanced Solid Tumors

Avenzo Therapeutics Recruiting Site, Cleveland

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/28更新 · NCT05867251

DESTINY-PANTUMOUR04

Research Site, Canton
Research Site, Maumee

被験者募集中観察研究

18歳〜130歳 · 全性別 · 2026/09/25更新 · NCT07124000

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

The Ohio State University Comprehensive Cancer Center, Columbus

被験者募集中観察研究

18歳以上 · 全性別 · 2026/09/25更新 · NCT04981119

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

The Ohio State University Wexner Medical Center, Columbus

被験者募集中第1/2相

18歳以上 · 女性 · 2026/09/25更新 · NCT03564340

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

The Ohio State University Wexner Medical Center, Columbus

被験者募集中第1/2相

18歳以上 · 女性 · 2026/09/24更新 · NCT04590326

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Research Site, Cincinnati
Research Site, Columbus

被験者募集中第2相

18歳〜130歳 · 全性別 · 2026/09/23更新 · NCT05489211

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Miami Valley Hospital South, Centerville
University of Cincinnati Medical Center, Cincinnati
Oncology Hematology Care Inc, Cincinnati
他7件

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/22更新 · NCT07213804

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Jamescare Gynecologic Oncology At Mill Run /ID# 277951, Hilliard

被験者募集中第2相

18歳以上 · 女性 · 2026/09/22更新 · NCT07059845

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

University of Cincinnati Medical Center ( Site 0042), Cincinnati

被験者募集中第3相

18歳以上 · 女性 · 2026/09/17更新 · NCT07318558

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

UH Cleveland Medical Center, Cleveland

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/17更新 · NCT07109726

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Cleveland Clinic Foundation, Cleveland
Ohio Health Research Institute, Columbus
Miami Valley Hospital South, Dayton
他1件

被験者募集中第3相

18歳以上 · 女性 · 2026/09/15更新 · NCT07214779

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Oncology Hematology Care, Inc, Cincinnati
The Mark H Zangmeister Cancer Center Ohio, Columbus
The Ohio State University Wexner Medical Center Division of Gynecologic Oncology, Hilliard

被験者募集中第2相

18歳〜99歳 · 女性 · 2026/09/15更新 · NCT07023627

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Cleveland Clinic, Cleveland
Toledo Clinic Cancer Center, Toledo

被験者募集中観察研究

18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

The Ohio State University Comprehensive Cancer Center, Hilliard

被験者募集中第2相

18歳以上 · 女性 · 2026/09/14更新 · NCT06787612

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Christ Hospital, Cincinnati
Ohio State University, Columbus

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/14更新 · NCT06303505

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Cleveland Clinic, Cleveland

被験者募集中第3相

18歳以上 · 女性 · 2026/09/14更新 · NCT04575935

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

Miami Valley Hospital South, Centerville
Zangmeister Cancer Center, Columbus

被験者募集中第3相

18歳以上 · 女性 · 2026/09/09更新 · NCT07225270

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

The Ohio State University (OSU) Wexner Medical Center, Columbus

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/04更新 · NCT06400472

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

University of Cincinnati Medical Center ( Site 0090), Cincinnati
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054), Columbus

被験者募集中第3相

18歳以上 · 女性 · 2026/09/03更新 · NCT06824467